

**CRDL2 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP4764b****Specification**

---

**CRDL2 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q6WN34](#)**CRDL2 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 25884**Other Names**

Chordin-like protein 2, Breast tumor novel factor 1, BNF-1, Chordin-related protein 2, CHRDL2, BNF1, CHL2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CRDL2 Antibody (C-term) Blocking Peptide - Protein Information****Name** CHRDL2**Synonyms** BNF1, CHL2**Function**

May inhibit BMPs activity by blocking their interaction with their receptors. Has a negative regulator effect on the cartilage formation/regeneration from immature mesenchymal cells, by preventing or reducing the rate of matrix accumulation (By similarity). Implicated in tumor angiogenesis. May play a role during myoblast and osteoblast differentiation, and maturation.

**Cellular Location**

[Isoform 1]: Secreted. [Isoform 3]: Cytoplasm. [Isoform 5]: Cytoplasm.

**Tissue Location**

Highly expressed in uterus. Moderately expressed in heart, liver, prostate, testis and ovary. Weakly expressed in skeletal muscle, kidney, spleen, small intestine and colon. Expressed in the secretory epithelial cells of uterine endometrium, fallopian tubes, endocervical glands, bladder and prostate, as well as the transitional epithelium of the urinary bladder, and in bone osteoblasts (at protein level). In normal cartilage, expression was confined in a few chondrocytes in the superficial zone as well as in the middle zone. In diseased cartilage coming from osteoarthritic patients,

expression was limited to the middle zone of chondrocytes. Isoform 1 and isoform 2 are expressed in fetal cerebellum and heart, while only isoform 2 is detected in fetal spleen. Isoform 2 present in plasma

### **CRDL2 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **CRDL2 Antibody (C-term) Blocking Peptide - Images**

### **CRDL2 Antibody (C-term) Blocking Peptide - Background**

CRDL2 may inhibits BMPs activity by blocking their interaction with their receptors. CRDL2 has a negative regulator effect on the cartilage formation/regeneration from immature mesenchymal cells, by preventing or reducing the rate of matrix accumulation (By similarity). CRDL2 implicated in tumor angiogenesis. CRDL2 may play a role during myoblast and osteoblast differentiation, and maturation.

### **CRDL2 Antibody (C-term) Blocking Peptide - References**

Yerges, L.M., et al. J. Bone Miner. Res. 24(12):2039-2049(2009)Zhang, Z., et al. Protein Sci. 13(10):2819-2824(2004)Oren, A., et al. Gene 331, 17-31 (2004)